UBX: Long, 450% profit
The price of 
UBX dropped over 60% after the announcement of bad results of the study of UBX0101 (treatment for knees osteoarthritis). Despite these bad results, UNITY Biotechnology has great potential since they do not focus only on one study. For example, they work on UBX1325, a treatment focused on retinal disease. In the last announcement, they state that they have enough money to fund operations well into 2022.
Enter price: Market
Price target: $15 or even more
This is an idea, but not advice.
UBX dropped over 60% after the announcement of bad results of the study of UBX0101 (treatment for knees osteoarthritis). Despite these bad results, UNITY Biotechnology has great potential since they do not focus only on one study. For example, they work on UBX1325, a treatment focused on retinal disease. In the last announcement, they state that they have enough money to fund operations well into 2022. Enter price: Market
Price target: $15 or even more
This is an idea, but not advice.
คำจำกัดสิทธิ์ความรับผิดชอบ
ข้อมูลและบทความไม่ได้มีวัตถุประสงค์เพื่อก่อให้เกิดกิจกรรมทางการเงิน, การลงทุน, การซื้อขาย, ข้อเสนอแนะ หรือคำแนะนำประเภทอื่น ๆ ที่ให้หรือรับรองโดย TradingView อ่านเพิ่มเติมที่ ข้อกำหนดการใช้งาน